A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, \>=18 years of age;
pancreatic cancer, surgically unresectable or with metastases;
no previous chemotherapy (except concomitant with radiotherapy);
ECOG 0-2.
You may not be if
pancreatic cancer without histologic or cytologic confirmation;
surgical resection possible;
previous chemotherapy not concomitant with radiotherapy;
ECOG 3-4.
Clareo Health | A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
